therapeutics News and Research

RSS

New transferrable and integrative type I CRISPR-based platform to efficiently edit superbugs

A research team led by Dr Aixin YAN, Associate Professor from the Research Division for Molecular & Cell Biology, Faculty of Science, in collaboration with Honorary Clinical Professor Patrick CY WOO from the Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, reported the development of a transferrable and integrative type I CRISPR-based platform.

23 Jul 2021

Researchers use body-on-a-chip cancer models to study personalized immunotherapy response

Wake Forest researchers and clinicians are using patient-specific tumor 'organoid' models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people.

20 Jul 2021

Study discloses neuroprotective properties of aromatic turmerone and its derivatives

Scientists discovered that aromatic turmerone and its derivatives have a direct effect on the dopaminergic nerves.

16 Jul 2021

$Microcrystal electron diffraction could help obtain potential pharmaceutical structures$

Microcrystal electron diffraction could help obtain potential pharmaceutical structures

In the process of drug development, solving structures of potential therapeutics with X-ray diffraction (XRD) has been a presumed, critical step so far.

16 Jul 2021

Genetic treatment may provide a new approach to addressing obsessive-compulsive disorder (OCD)

For the first time, scientists have linked distinct patterns of genetic mutations with OCD in humans using genome-wide analysis.

29 Jun 2021

WEHI partners with Boehringer Ingelheim to develop novel anti-cancer therapeutics

WEHI has partnered with Boehringer Ingelheim, a leading research-driven pharmaceutical company, in a collaboration to discover and develop anti-cancer therapeutics using a promising new technology called targeted protein degradation.

From Walter and Eliza Hall Institute of Medical Research (WEHI) 25 Jun 2021

Scientists reveal key role of glial protein in building the brain

When we think of the brain, we think of neurons. But much of the brain is made of non-neuronal cells called glial cells, which help regulate brain development and function.

25 Jun 2021

Scientists explore the human gut to combat SARS-CoV-2 virus

Scientists have discovered that some commensal bacteria residing in the human gut release compounds that suppress the SARS-CoV-2 virus.

21 Jun 2021

Researchers discover new way to improve absorption and brain delivery of medicinal cannabis

A team of researchers led by Curtin University has discovered a new way to improve the absorption rate of medicinal cannabis when taken orally, which could potentially be used to treat neurological disorders such as Alzheimer’s disease, multiple sclerosis and traumatic brain injuries in the future.

21 Jun 2021

Naked mole rats' unique DNA repair mechanism helps prevent cancers, dementia

Scientists say naked mole rats - a rodent native to West Africa - may hold the key to new treatments for degenerative diseases such as cancer and dementia.

11 Jun 2021

Pre-trained viruses are more effective in countering antibiotic resistance

The risk of antibiotic resistance increases as bacteria continue to evade even the most powerful contemporary medicinal treatments. Antibiotic-resistant microorganisms threaten to take more than 10 million lives by 2050, as present-day treatments prove ineffective.

9 Jun 2021

Scientists discover two drugs that provide effective SARS-CoV-2 suppression

COVID-19 continues to claim lives across the world and is infecting millions more. Although several vaccines have recently become available, making significant strides towards preventing COVID-19, what about the treatment of those who already have the infection?

From Tokyo University of Science 4 Jun 2021

Researchers identify new therapeutic targets for flaviviruses

In a recent study, Australian scientists used an original approach to resolve the 3D structure of flaviviruses with an unprecedented level of detail, identifying small molecules known as 'pocket factors' as new therapeutic targets.

2 Jun 2021

Understanding molecular determinants of liver cancer in patients with Indigenous American ancestry

Oncotarget published "Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry" which reported that contrasting with this pattern, the age structure of HCC in Andean people displays a bimodal distribution with half of the patients developing HCC in adolescence and early adulthood.

2 Jun 2021

Study discovers novel function for metabolic enzyme medium-chain acyl-CoA dehydrogenase

Scientists have come up with an innovative function for the metabolic enzyme medium-chain acyl-CoA dehydrogenase (MCAD) in glioblastoma (GBM).

1 Jun 2021

Scientists identify mechanism by which head and neck cancer cells subvert adjacent normal tissue

Up to half of patients with head and neck squamous cell carcinoma will experience tumor recurrence or new tumors--tumors that often spread and are difficult to treat.

28 May 2021

Latest articles provide novel insights into the mechanisms driving pridopidine neuroprotective effects

Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announces the publication of three peer-reviewed journal articles, highlighting key aspects of the mechanism of action of its lead asset, pridopidine, and the importance of S1R activation as a mechanism to attenuate biological features of neurodegenerative diseases.

25 May 2021

Study could help develop peptide siRNA carrier for human oral cancer

MUSC Hollings Cancer Center researchers are exploring the use of peptide carriers for the delivery of small RNA drugs as a novel treatment for cancer. The team's recent work, published online March 19 in the Molecular Therapy - Nucleic Acids journal, lays the foundation for developing a clinically relevant peptide carrier RNAi-based drug treatment strategy for human oral cancer.